| Literature DB >> 30127752 |
Shuzhan Gao1,2, Shuiping Lu1,2, Xiaomeng Shi1,2, Yidan Ming1,2, Chaoyong Xiao3, Jing Sun1,2, Hui Yao1,2, Xijia Xu1,2.
Abstract
Background: Patients with treatment-resistant schizophrenia (TRS) and non-treatment-resistant schizophrenia (NTRS) respond to antipsychotic drugs differently. Previous studies demonstrated that patients with TRS or NTRS exhibited abnormal neural activity in different brain regions. Accordingly, in the present study, we tested the hypothesis that a regional homogeneity (ReHo) approach could be used to distinguish between patients with TRS and NTRS.Entities:
Keywords: function magnetic resonance imaging; left inferior frontal gyrus; left postcentral gyrus; non-treatment-resistant schizophrenia; regional homogeneity; right fusiform; treatment-resistant schizophrenia
Year: 2018 PMID: 30127752 PMCID: PMC6088138 DOI: 10.3389/fpsyt.2018.00282
Source DB: PubMed Journal: Front Psychiatry ISSN: 1664-0640 Impact factor: 4.157
Demographic and clinical characteristics of participants.
| Age (year) | 31.24 ± 9.40 | 36.82 ± 9.12 | 32.73 ± 7.61 | 0.119 | |
| Sex(male/female) | 10/7 | 9/8 | 16/13 | 0.378 | |
| Nation(Han/others) | 17/0 | 17/0 | 29/0 | – | |
| handedness(right/left) | 17/0 | 17/0 | 29/0 | – | |
| Education | 12.24 ± 2.93 | 13.76 ± 3.58 | 14.28 ± 3.10 | 0.568 | |
| (year) | |||||
| Onset (year) | 17.24 ± 2.19 | 29.18 ± 8.95 | – | 0.001 | |
| Duration(year) | 14.00 ± 8.75 | 7.88 ± 4.72 | – | < 0.001 | |
| PANSS | Total | 97.76 ± 11.10 | 37.29 ± 6.84 | – | < 0.001 |
| Positive | 27.53 ± 5.95 | 9.53 ± 3.14 | – | < 0.001 | |
| Negative | 21.05 ± 3.91 | 8.41 ± 1.91 | – | < 0.001 | |
| General | 49.12 ± 5.54 | 19.24 ± 2.63 | – | < 0.001 | |
| CED (mg/day) | 696.47 ± 208.92 | 436.76 ± 237.85 | – | 0.002 |
TRS: treatment-resistant schizophrenia, NTRS: non-treatment-resistant schizophrenia, HCs: healthy controls, CED: chlorpromazine equivalent dose, PANSS: Positive and Negative Syndrome Scale.
Figure 1Brain regions showing significant group differences of ReHo in patients relative to controls by using ANCOVA. ReHo, regional homogeneity; ANCOVA, analyses of covariance.
Post-hoc t tests analysis for differentiating patients from controls.
| Left Postcentral Gyrus | −51 | −12 | 21 | 42 | 4.4910 |
| Right Angular Gyrus | 51 | −75 | 36 | 28 | −4.2643 |
| Right Fusiform Gyrus | 42 | −39 | −18 | 54 | −4.3036 |
| Right Middle frontal gyrus, orbital part | 30 | 42 | −15 | 35 | 4.8364 |
| Right Putamen | 24 | 15 | −3 | 47 | 4.4017 |
| Left Middle Occipital Gyrus/ Middle Temporal Gyrus | −45 | −72 | 6 | 224 | −4.7905 |
| Right Middle Occipital Gyrus/Middle Temporal Gyrus | 48 | −66 | 6 | 116 | −4.3776 |
| Left Inferior frontal gyrus, triangular part | −42 | 21 | 12 | 146 | 5.9131 |
| Right Inferior frontal gyrus, triangular part | 45 | 18 | 12 | 79 | 4.4111 |
| Right Superior Occipital Gyrus | 21 | −93 | 21 | 83 | −4.2365 |
| Bilateral Superior medial frontal gyrus | 3 | 36 | 45 | 98 | 5.2095 |
| Right Superior Parietal Lobule | 21 | −54 | 63 | 37 | −4.4150 |
| Right Fusiform Gyrus | 42 | −45 | −24 | 69 | −5.0679 |
| Right Inferior Occipital Gyrus | 33 | −84 | −9 | 147 | −5.0194 |
| Left Middle Occipital Gyrus/ Middle Temporal Gyrus | −45 | −69 | 9 | 40 | −3.9240 |
| Left Angular Gyrus | −42 | −72 | 33 | 80 | 4.7123 |
| Right Angular Gyrus | 48 | −72 | 36 | 65 | 5.1926 |
| Left Postcentral Gyrus | −39 | −36 | 60 | 37 | −4.5169 |
A positive/negative t value represents an increased/decreased ReHo; MNI = Montreal Neurological Institute; ReHo = regional homogeneity; TRS: treatment-resistant schizophrenia; NTRS: non-treatment-resistant schizophrenia; HC: healthy controls.
Figure 2Abnormal ReHo across groups. Red and blue denote increased and decreased ReHo values. Color bar indicates post-hoc t-values. ReHo, regional homogeneity.
ROC analysis for differentiating patients from controls.
| Right Angular Gyrus | 0.792 | −0.1746 | 70.59% (12/17) | 100% (17/17) |
| Left Postcentral Gyrus | 0.889 | −0.0966 | 94.12% (16/17) | 82.35% (14/17) |
| Left Inferior frontal gyrus, triangular part | 0.949 | −0.1112 | 100% (17/17) | 86.21% (25/29) |
| Right Inferior frontal gyrus, triangular part | 0.856 | −0.0564 | 70.59% (12/17) | 96.55% (28/29) |
| Right Middle frontal gyrus, orbital part | 0.872 | −0.1886 | 76.47% (13/17) | 82.76% (24/29) |
| Bilateral Superior medial frontal gyrus | 0.844 | 0.1511 | 88.24% (15/17) | 75.86% (22/29) |
| Right Fusiform Gyrus | 0.872 | −0.0830 | 94.12% (16/17) | 75.86% (22/29) |
| Left Middle Occipital Gyrus/ Middle Temporal Gyrus | 0.874 | 0.0899 | 100% (17/17) | 68.97% (20/29) |
| Right Superior Occipital Gyrus | 0.819 | −0.0412 | 76.47% (13/17) | 75.86% (22/29) |
| Right Superior Parietal Lobule | 0.832 | 0.0334 | 64.71% (11/17) | 93.10% (27/29) |
| Right Putamen | 0.797 | 0.1480 | 52.94% (9/17) | 96.55% (28/29) |
| Right Middle Occipital Gyrus/Middle Temporal Gyrus | 0.888 | 0.0391 | 94.12% (16/17) | 72.41% (21/29) |
| Left Angular Gyrus | 0.852 | 0.0619 | 94.12% (16/17) | 68.97% (20/29) |
| Right Angular Gyrus | 0.872 | 0.0145 | 94.12% (16/17) | 72.41% (21/29) |
| Right Fusiform Gyrus | 0.903 | −0.1407 | 82.35% (14/17) | 93.10% (27/29) |
| Right Inferior Occipital Gyrus | 0.862 | 0.0203 | 70.59% (12/17) | 89.66% (26/29) |
| Left Postcentral Gyrus | 0.848 | 0.0176 | 82.35% (14/17) | 79.31% (23/29) |
| Left Middle Occipital Gyrus/ Middle Temporal Gyrus | 0.834 | 0.1591 | 94.12% (16/17) | 72.41% (21/29) |
By this cut-off point, the ReHo value in the right angular gyrus could correctly classify 12 of 17 treatment-resistant patients and 17 of 17 treatment-non-refractory patients, resulted in a sensitivity of 70.59% and a specificity of 100%. The meanings of other cut-off points were similar. ROC = receiver operating characteristic curves.
Figure 3Receiver operating characteristic (ROC) curves of the optimal sensitivity and specificity by using ReHo values in the left postcentral gyrus, left inferior frontal gyrus, and right fusiform gyrus to differentiate treatment-resistant schizophrenia patients from non-resistant schizophrenia patients, treatment-resistant patients from healthy controls, and non-treatment-resistant schizophrenia patients from healthy controls, respectively. ReHo, regional homogeneity; IFG, inferior frontal gyrus.